1. Male or female participants age of \>1 month to \<18 years (Cohort 1: ≥13 to \<18 years, Cohort 2: \>1 month to \<13 years).
2. Dry weight ≥7 kg during screening.
3. Diagnosed with Chronic Kidney Disease (CKD) and secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis at the time of screening.
You may not be if
1. History of congenital long QT syndrome, second- or third-degree heart block, ventricular tachyarrhythmias, or other conditions associated with prolonged QT interval.
2. Anticipated parathyroidectomy during the study period.
3. Scheduled kidney transplant during the study period.
4. Participants received a parathyroidectomy within 6 months prior to randomization.
5. Receipt of cinacalcet therapy within 4 weeks prior to screening assessments and through randomization.
6. Receipt of etelcalcetide within 6 months prior to screening assessments and through randomization.
